Yuro Haruta
About
In The Last Decade
Yuro Haruta
22 papers receiving 738 citations
Peers
Comparison fields: 5 of 65
- Molecular Biology 499
- Oncology 241
- Cancer Research 178
- Radiology, Nuclear Medicine and Imaging 148
- Pulmonary and Respiratory Medicine 116
Countries citing papers authored by Yuro Haruta
This map shows the geographic impact of Yuro Haruta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuro Haruta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuro Haruta more than expected).
Fields of papers citing papers by Yuro Haruta
This network shows the impact of papers produced by Yuro Haruta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuro Haruta. The network helps show where Yuro Haruta may publish in the future.
Co-authorship network of co-authors of Yuro Haruta
This figure shows the co-authorship network connecting the top 25 collaborators of Yuro Haruta. A scholar is included among the top collaborators of Yuro Haruta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuro Haruta. Yuro Haruta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 110 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | Differential expression of endoglin (CD105) between human malignant epithelial tissues and cultured epithelial cell lines | 1 |
| 6 | 38 | |
| 7 | Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. | 102 |
| 8 | Angiogenesis and metastasis marker of human tumors. | 9 |
| 9 | 63 | |
| 10 | Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. | 137 |
| 11 | 3 | |
| 12 | Establishment of ascitic tumor of human pre-B acute lymphoblastic leukemia in nonconditioned nude mice. | 9 |
| 13 | Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. | 24 |
| 14 | Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies. | 11 |
| 15 | 52 | |
| 16 | New monoclonal antibodies SN3, SN3a, and SN3b directed to sialic acid of glycoprotein on human non-T leukemia cells. | 7 |
| 17 | 15 | |
| 18 | 1 | |
| 19 | 4 | |
| 20 | 20 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.